• 4/19/2008
  • London, England
  • press release
  • CNNMoney.com

Introgen Therapeutics Inc. said Monday its Advexin phase three clinical trial data in patients with recurrent head and neck cancer has confirmed earlier phase two results of the drug’s efficacy.

‘Advexin provides therapeutic benefit by restoring p53 tumor suppressor function which is blocked in the majority of head and neck cancers,’ Robert E. Sobol, senior vice president, medical and scientific affairs, Introgen said in a statement.

A comprehensive analysis of Introgen’s phase three data and additional studies of Advexin will be presented at medical conferences later this year. These and other data will be the basis for regulatory submissions in the United States and in Europe as previously reported, the company said.